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Available online 2 February 2016It is widely accepted that efﬁcacy and speed of current antidepressants' therapeutic effect are far from optimal.
Thus, there is a need for the development of antidepressants with newmechanisms of action. The neuropeptide
galanin and its receptors (GalR1, GalR2 and GalR3) are among the promising targets. However, it is not clear
whether or not the galanin system is involved in the antidepressant effect exerted by the currently much used
inhibitors of the reuptake of serotonin and/or noradrenaline. To answer this questionwe administered the selec-
tive serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine (40 mg/kg/day via osmotic minipumps)
to normal rats and examined the levels of the transcripts for galanin and GalR1–3 after a 3-week venlafaxine
treatment in the dorsal raphe, hippocampus and frontal cortex. These areas are known to be involved in the ef-
fects of antidepressants and in depression itself. Venlafaxine failed to alter the expression of any of the galanin
system genes in these areas. Our results show that one of the most efﬁcient, currently used SNRIs does not
alter transcript levels of galanin or its three receptors in normal rats. These ﬁndings suggest that the pro- and
antidepressive-like effects of galanin reported in animal experiments may employ a novel mechanism(s).
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Transcripts1. Introduction
Major depressive disorder (MDD) is amongst the most debilitating
diseases of modern societies (Han and Wang, 2005; Kessler et al.,
2006). While pharmacological treatments do exist, they lack effective-
ness in many individuals (O'Leary et al., 2015; Pigott et al., 2010;
Thase et al., 2005; Trivedi et al., 2006), they cannot always prevent fur-
ther depressive episodes (Pigott et al., 2010; Trivedi et al., 2006) and
they have a delay in the onset of their therapeutic effect (Gex-Fabry
et al., 2004; Machado-Vieira et al., 2008; O'Leary et al., 2015; Smith
et al., 2002). Thus, research is ongoing for discovering better
antidepressant treatments and new possible targets (O'Leary et al.,
2015). In these efforts the galanin system has emerged as a candidate
for further exploration (Counts et al., 2008; Elvander et al., 2004;
Holets et al., 1988; Lang et al., 2015; Pieribone et al., 1998; Senut et al.,
1989; Skoﬁtsch et al., 1986; Weiss et al., 1998; Xu and Hokfelt, 1997).amics, Semmelweis University,
. This is an open access article underGalanin is a 29 amino acid long neuropeptide (Tatemoto et al., 1983)
acting via three G-protein coupled receptors, Gal1, Gal2 and Gal3
(Barreda-Gomez et al., 2014; Branchek et al., 2000; Lang et al., 2015).
Galanin and the Gal1–3 receptors are widely distributed in the rat
(Melander et al., 1986; O'Donnell et al., 2002; Skoﬁtsch and
Jacobowitz, 1985; Skoﬁtsch et al., 1986) and human (Kohler et al.,
1989; Kordower et al., 1992) brain, and among their many functions is
the modulation of the brain's serotonin (5-HT) and noradrenaline
(NA) neurons (Fuxe et al., 1998; Pieribone et al., 1998; Weiss et al.,
1998). This was further supported by the fact that all three receptors
are found in the dorsal raphe (DR) and locus coeruleus (LC) of rats
(Burazin et al., 2000; Mennicken et al., 2002; O'Donnell et al., 1999,
2002) and that galanin is co-expressed in almost 40% of the serotonergic
neurons in the DR (Xu and Hokfelt, 1997) and in around 80% of the nor-
adrenergic neurons in the LC (Holets et al., 1988). However, reports in-
dicate that galanin also modulates GABAergic (Sharkey et al., 2008) and
cholinergic neurotransmission (Counts et al., 2008; Elvander et al.,
2004; Senut et al., 1989) and may thus directly and indirectly inﬂuence
functions in distinct regions, such as the hippocampus (HC) and frontal
cortex (FC). Functionally, galanin has been suggested to be implicated in
numerous pathological states and physiological processes in the centralthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sy (Kovac and Walker, 2013; Lerner et al., 2008), addiction (Picciotto,
2010) or pain perception (Xu et al., 2008), but particular focus has
been on depressive states and anxiety-related disorders/behaviors
(Fuxe et al., 1998; Kuteeva et al., 2008a, 2008b; Lu et al., 2007; Murck
et al., 2004). Indeed, studies showed that a Gal3 antagonist (Swanson
et al., 2005) and a Gal2 agonist (Kuteeva et al., 2008b; Lu et al., 2005;
Saar et al., 2013a, 2013b) attenuated depressive symptoms in rodent
models of depression, while recent association studies by Wray et al.
(2012) and Juhasz et al. (2014) have underlined the importance of poly-
morphisms in the galanin genes in humans. However, increase in
galanin releasemay exert opposite effects on depression related pheno-
types. In general terms, reports cited above indicate that activation of
Gal1 andGal3 causes depression-like effects, while blockade of these re-
ceptors and activation of Gal2 were associated with antidepressant-like
effects in the behavior of rats.
The galanin-like peptide precursor (Galp) encodes two transcripts
related to the galanin system which are formed through splicing. One,
Galp, was isolated from porcine hypothalamus and considered original-
ly as a possible Gal2 agonist (Ohtaki et al., 1999). Later its agonistic
properties have also been demonstrated for Gal1 and Gal3 in
transfected cells, and results from knock-out mice raised the possibility
of a so far undiscovered native receptor for the peptide (Krasnow et al.,
2004; Lang et al., 2005, 2015). The expression of Galp is restricted to
speciﬁc cells in the hypothalamus, its release is regulated by e.g. insulin
and leptin (Jureus et al., 2000, 2001) and once released, it inﬂuences
feeding behavior and thermogenesis (Hansen et al., 2003; Lawrence
et al., 2002; Matsumoto et al., 2002). While feeding irregularities may
accompany mood disorders, so far, no link was demonstrated between
Galp and depression/antidepressant actions.
The other transcript is alarin, a result of alternate splicing of Galp,
which contains 25 amino acids (Santic et al., 2006, 2007). Alarin cannot
bind to Gal1–3 and has no identiﬁed receptors so far (Lang et al., 2015),
but is considered as a galanin system peptide because of its origin. Its
distribution in the rodent brain contrasts that of the galanin-like pep-
tide: it is abundant in cortical layers, the HC and the LC in mice among
many other areas (Eberhard et al., 2012). Functionally alarin is involved
in the regulation of feeding behavior and the modulation of the hypo-
thalamus–pituitary–adrenal (HPA) axis (Fraley et al., 2012; Van Der
Kolk et al., 2010). In addition, alarin has been implicated in depression
by the recent studies of Wang et al., who proposed central roles for
the modulation of hypothalamic hormones, the brain-derived neuro-
trophic factor and TrkB in its anti-depressive effects (Wang et al.,
2014, 2015).
In rats, chronic ﬂuoxetine (FLX) and paroxetine (PRX) treatments,
which belong to the selective serotonin reuptake inhibitor (SSRI) class
of antidepressants, elevated galanin expression in the DR (Lu et al.,
2005; Rovin et al., 2012). In mice, chronic sertraline, another SSRI, or
FLX treatments were able to induce similar changes in the HC region
(Christiansen et al., 2011; Yamada et al., 2013). At the same time, chronic
treatment with phenelzine (PLZ), a monoamino-oxidase inhibitor
(MAOI) failed to cause any alterations in the gene expression of galanin
and its receptors in the DR of rats (Rovin et al., 2012). The latter result
suggests that the effects on galanin and Gal1–3 are not uniform among
antidepressants and may be related to certain pharmacological proper-
ties. However, neither galanin, nor galanin receptor or Galp gene expres-
sion was studied after administration of a serotonin-noradrenaline or
selective noradrenaline reuptake inhibitor antidepressant.
Venlafaxine (VLX) belongs to a group of drugs with an extended
mechanism of action compared to SSRIs, that is they selectively inhibit
both serotonin and noradrenaline reuptake (SNRIs). It has been used
widely in clinical practice and been proven to be more effective than
SSRIs in terms of economic costs, remission rates and earlier onset of an-
tidepressant actions (Gex-Fabry et al., 2004; Smith et al., 2002). VLX has
been shown to activate expression of a number of genes, for example
such involved in neurotrophic signaling, glutamatergic transmission,neuroplasticity, synaptogenesis and cognitive processes (Tamasi et al.,
2014). Interactions between noradrenergic neurotransmission and
galanin signaling have been already discussed in the literature [for re-
views see (Lu et al., 2007)], while those with the serotonergic system
are described above. Thus, it is tempting to speculate that, if SSRIs are
able to modulate galanin signaling, this may also be the case with
SNRIs, in fact the effect could be enhanced.
In this report we present the results of a gene expression analysis of
the galanin, Gal1, Gal2 and Gal3 and Galp genes from the DR, HC and FC
regions of Dark Agouti (DaAg) rats following 3-week long chronic VLX
treatment.
2. Materials and methods
The presented experiment was part of a large-scale microarray
study, thus the methods used in this study are discussed in details in
(Petschner et al., 2013; Tamasi et al., 2014), and here we only provide
a brief description.
2.1. Animals and drugs
In this study altogether 20male, DaAg rats (Harlan, Olac Ltd., Shaw's
Farm, Blackthorn, Bicester, Oxon, UK, aged: 8 weeks, weighing
126.85 ± 4.22 g (mean ± S.E.M.) were used. The animal experiments
and housing conditions were carried out in accordance with the
European Community Council Directive of 24 November 1986 (86/609/
EEC), the National Institutes of Health Principles of Laboratory Animal
Care (NIH Publication 85-23, revised 1985) and special national laws
(the Hungarian Governmental Regulation on animal studies, 31 Decem-
ber 1998 Act). The experiments were approved by the National Scientiﬁc
Ethical Committee on Animal Experimentation and permitted by the
Food Chain Safety and Animal Health Directorate of the Central Agricul-
tural Ofﬁce, Hungary (permission number: 22.1/3152/001/2007).
VLX was dissolved in 0.9% NaCl solution, and Alzet 2001 osmotic
minipumps (Durect Corp., CA, USA) were ﬁlled with the solution.
2.2. Drug administration and experimental design
Alzet osmotic minipumps were inserted subcutaneously under the
back skin of the rats in the VLX-groups while the control group
underwent sham surgery. All surgery was performed under anesthesia
with halothane. Due to the limited volume of the osmotic pumps, the
sham surgery and minipump insertion had to be repeated every week
for 3 weeks. The pumps delivered 40 mg/kg VLX each day, while food
and water were available ad libitum. During surgical procedures one
animal died, thus, altogether 19 animals were used in the experiments.
2.3. RNA extraction and sample preparation
Three weeks after the ﬁrst osmotic minipump insertion rats were
killed quickly by decapitation. The brainswere removed, approximately
2 mm thick coronal sections were cut and the HC, FC and DR regions
were dissected according to the Atlas of Paxinos and Watson (Paxinos
and Watson, 1986) as follows: dorsal HC: from bregma −2.5 mm to
−4.5 mm; FC: from bregma +1.7 to −0.3 mm; DR: from bregma
−7 mm to−8 mm, respectively, and stored at−80 °C. The samples
were homogenized with 1 ml TRIzol reagent and RNA was isolated.
The pellets were dissolved in 20 μl diethylpyrocarbonate treated-
dH2O (DEPC-dH2O) and solutions stored at−80 °C. The optical density
(OD) ratios were determined for all samples for quality check and
randomly repeated to evaluate the reliability of the measurements (no
signiﬁcant difference was observed, data not shown). Thereafter two-
two randomly selected samples from the same treatment groups and
region with the best OD ratios were pooled, resulting in altogether
four pooled samples per treatment and region. From VLX treated and
vehicle treated pools microarray experiments were performed by
Table 1
Galanin genes in different brain regions following a 3-week long VLX treatment of Dark
Agouti rats.
A)
Minimum probability of positive log
ratio values in different brain regions
Gal Gal1 Gal2 Gal3 Galp
Brain regions
Frontal cortex 0.397 0.225 0.351 0.450 0.395
Hippocampus 0.425 0.249 0.332 0.427 0.471
Dorsal raphe 0.333 0.327 0.017 0.466 0.429
B)
Fold change values in different brain
regions
Gal Gal1 Gal2 Gal3 Galp
Brain regions
Frontal cortex 0.05 0.08 −0.06 0.10 −0.13
Hippocampus −0.07 0.06 0.06 0.09 0.04
Dorsal raphe 0.12 −0.02 −0.22 0.04 −0.04
C)
The adjusted p-values in different brain
regions after linear model ﬁt
Gal Gal1 Gal2 Gal3 Galp
Brain regions
Frontal cortex 0.76 0.83 0.94 0.80 0.76
Hippocampus 0.99 0.99 0.99 0.99 0.99
Dorsal raphe 0.91 0.94 0.70 0.91 0.94
Table 2
Average expression values of the galanin genes in the control animals.
Average expression values in different
brain regions in the control group
Gal Gal1 Gal2 Gal3 Galp
Brain regions
Frontal cortex 141.70 88.76 152.30 107.89 137.41
Hippocampus 153.36 89.25 149.43 109.10 126.08
Dorsal raphe 436.21 89.74 233.35 110.94 120.90
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Beadarray Expression Chip, San Diego, CA, USA).
2.4. Data analysis
Rawmicroarray datawere processedwith beadarray (Dunning et al.,
2007), preprocessCore (Bolstad) and puma (Pearson et al., 2009)
Bioconductor (Gentleman et al., 2004) packages for R (R Core Team,
2012) as described in Alttoa et al. (2010). Brieﬂy, backgroundCorrect
method used in the beadarray package was set to “minimum”, and
“log= TRUE; n= 10” variables were used for createbeadsummaryData
method. The normalization method was quantile normalization in the
preprocessCore package. PumaComb, pumaDE, andwrite.rslts functions
with default settings were used. Changes were considered statistically
signiﬁcant when the minimum probability of positive log ratio
(MinPplr), a Bayesian-based value of signiﬁcance, was below 0.001.
This is a necessary and usual restriction to avoid false positive results
in microarray experiments.
Data supporting the current results have been deposited in NCBI's
Gene Expression Omnibus (Edgar et al., 2002) and are accessible
through GEO Series accession number GSE47541 (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE47541).
2.5. PCR validation
We have validated altogether 19 RNA products from the original
pooled samples with real-time quantitative polymerase chain reaction
(qPCR) on a Fluidigm GEx array (San Francisco, CA, USA) using Taqman
Gene Expression assays for the appropriate RNAs obtained fromApplied
Biosystems (Carlsbad, CA, USA). The validation experiment was per-
formed by ServiceXS (Leiden, Netherlands). Upon arrival of the normal-
ized results, manually written R scripts using the cor.test function with
default settings were used for the comparison between microarray and
qPCRdata. The Pearson correlation coefﬁcientswere 0.631 and 0.656 for
the 200 ng and 500 ng samples, respectively, with p-values 5.3 × 10−14
and 2.2 × 10−15.
2.6. Linear models
To statistically further validate the results on the galanin system's
gene expression, linear models were ﬁt on the normalized and
background corrected microarray data using LIMMA (Smyth, 2005), a
Bioconductor (Gentleman et al., 2004) package for R (R Core Team,
2012). During the analysis lmFit and eBayes functions with default set-
tings were used. To obtain adjusted p-values the topTable function
with the false discovery ratio (Benjamini and Hochberg, 1995) correc-
tionwas used, a more permissive and acceptedmethodology for the re-
duction of false positive results than the stringent Bonferroni correction
(Petschner et al., 2015).
3. Results and discussion
The antidepressant VLX was unable to alter the expression of
galanin, Gal1, Gal2, Gal3 and Galp genes in the DR, HC and FC of DaAg
rats (Table 1.).
Table 1/A. shows the minimum probability ratios for the galanin
(Gal), galanin receptor 1 (Gal1), galanin receptor 2 (Gal2), galanin re-
ceptor 3 (Gal3) and galanin-like peptide precursor (Galp) genes in the
examined brain regions following 40 mg/kg/die VLX treatment for
3 weeks (administered via osmotic minipumps implanted under the
back skin) in Dark Agouti rats. Based on the minimum probability of
positive log ratio (minPplr) method, only the Gal2 gene showed some
alterations, however, due to all the genes represented on a singlemicro-
array plate, to avoid false positive results only values below 0.001 could
have been considered signiﬁcant. Table 1/B. shows the respective fold
change values of theGal, Gal1, Gal2, Gal3 andGalp genes in the differentbrain regions. Table 1/C. represents the false discovery ratio adjusted
p-values of the VLX treated rats compared to the control animals
using linear models, a basically different mathematical model than the
minPplr method. The calculations were performed to provide further
statistical support of the conclusions drawn in the paper. Fold change
values are per deﬁnitionem the same for both methods.
Table 2. shows the average, background corrected and normalized
expression intensities for galanin system genes in the control animals.
Since VLX caused no signiﬁcant alterations in the level of these
mRNAs a table containing those data is not included.
Several studies have explored the effects of various SSRIs and other
drugs on the galanin system in different rodent experimental models.
In the HC, Yamada and coworkers treated mice 4-week long with the
SSRI sertraline and examined galanin in the dorsal and ventral dentate
gyrus of mice (Yamada et al., 2013), where galanin was upregulated in
the ventral but not in the dorsal dentate gyrus. Christiansen et al. com-
bined a 14-day long FLX treatment with chronic restraint stress and
found signiﬁcantly elevated galanin expression in the dorsal HC, when
compared with both stress-exposed and -unexposed rats without phar-
macological intervention (Christiansen et al., 2011). Similarly, in the DR,
Lu and coworkers have shown that chronic FLX could elevate galanin
mRNA levels and Gal2-binding sites in the DR of rats (Lu et al., 2005).
Rovin et al. studied chronic treatment (14 days) of Sprague–Dawley
rats with the SSRI paroxetine and recorded, among others, elevated
galanin levels in the DR; however, a 14-day long treatment with PLZ
via osmotic minipumps failed to alter the expression of galanin (Rovin
et al., 2012). PLZ, besides elevating 5-HT levels, also causes an increase
in the level of NA and dopamine through inhibition of monoamine oxi-
dases (Christmas et al., 1972) and inﬂuences so called trace amines, like
2-phenlyethylamine, tryptamine, octopamine, and tyramine (Baker
et al., 1992).
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VLX, the “ﬂagship” of SNRI antidepressants, on the expression of the
galanin and its receptors' genes in the FC, HC and DR of normal DaAg
rats. This is somewhat surprising, since VLX, like the above mentioned
FLX and sertraline, potently inhibits the reuptake of 5-HT. One possible
explanation is the fact that VLX also inhibits reuptake of NA causing an
increase in extracellular concentration of this catecholamine. This
hypothesis is supported by the fact that the MAO inhibitor PLZ, which
also causes a parallel increase in 5-HT andNA, failed to cause any change
in the expression of galanin and Gal1–3 in rats, indeed in four brain re-
gions including DR (Rovin et al., 2012).
There is no direct evidence whether the increase of galanin gene
expression by SSRIs increases or decreases their antidepressant proper-
ties. As discussed earlier, stimulation of Gal2may cause antidepressant-
like, stimulations of Gal1 andGal3 receptors a pro-depressive effect. Our
results may shed some light on this question. VLX as an antidepressant
is at least as potent as the SSRIs, but without any effect on the galanin
system. Thus, it is unlikely that the increased expression of galanin
caused by the SSRIs is an important mediator of their antidepressant
effects.
To what extent changes in galanin gene expression by SSRIs are
responsible for antidepressant effect remains to be further analyzed in
detail. However, as discussed earlier, stimulation of Gal2 may cause an
antidepressant-like effect. If so, Lu et al.'s demonstration of FLX-
induced increases in both galanin mRNA and, likely, Gal2 receptors
(Lu et al., 2005), could result in a robust antidepressive effect. However,
elevated galanin expression observed after chronic SSRI treatmentsmay
not necessarily represent beneﬁcial changes in antidepressant proper-
ties. As earlier mentioned, stimulation of Gal2 may mediate
antidepressant-like, whereas stimulation of Gal1 and Gal3 receptor a
pro-depressive effect. The Gal1 receptor agonist, M617 augmented im-
mobility time in the forced swimming test (Lundstrom et al., 2005),
while Gal3 antagonists were able to reduce anxiety- and depression-
like behavior in various models (Barr et al., 2006; Swanson et al.,
2005). Gal3 KO mice exhibited an anxiety-like phenotype (Brunner
et al., 2014), and decreased motivation elicited in mice by chronic pain
requires a Gal1-triggered mechanism in the nucleus accumbens
(Schwartz et al., 2014). At the same time, a Gal2 (and to a lesser extent
Gal3) receptor agonist, AR-M1896, showed antidepressant properties
(Kuteeva et al., 2008b). In accordance, i.c.v. administration of galanin
on its own resulted in elevated immobility times in the forced swim-
ming test in Sprague–Dawley rats, suggesting that elevated galanin
levels may only have antidepressant properties when accompanied by
decreased Gal1 and Gal3, or elevated Gal2 receptor expression or bind-
ing sites (Kuteeva et al., 2008b; Lu et al., 2005). This indicates thatmood
behavior may be inﬂuenced by a balance between different subtypes of
activated galanin receptors.
Most of the studies using antidepressant treatments did not examine
receptor levels to predict more exact consequences of the elevated
galanin mRNA levels. Although, upregulated within the DR after FLX
treatment (Lu et al., 2005), Gal2 receptors may also be of importance
within the hippocampal formation. Thus, among the three galanin re-
ceptors, a robust expression of Gal2s has been demonstrated in the
granule cells in the dentate gyrus (Burazin et al., 2000; O'Donnell
et al., 1999). However, only one study has evaluated Gal2 levels from
the HC following chronic sertraline treatment and reported elevated
galanin, but unaltered Gal2 mRNA levels (Yamada et al., 2013).
We simultaneously examined the effects of an SNRI on the expres-
sion of galanin itself and its three receptors in the HC, DR and FC,
showing a total lack of changes. Previous results from similar type of
studies show that changes in galanin gene expression after chronic
SSRI are difﬁcult to interpret—are increases or decreases related to an
antidepressant effect? Our study is unique in that VLX targets both the
5-HT and NA transporter, thus increasing extracellular levels of both
monoamines. One conclusion is that the mechanism of antidepressant
action of VLX likely does not include an effect via the galanin system.Since VLX is at least as potent as the SSRIs in treatment of depression,
the signiﬁcance of increased expression of galanin caused by the SSRIs
remains to be further examined. It may be noted that the three mono-
amine systems, 5-HT, NA and dopamine are all connected. For example,
it is known that the enhancement of 5-HT signaling after SSRIs will
dampen the activity of the NA (and dopamine) neurons. Also the effects
on certain monoamine receptors are different: SSRIs downregulate
somato-dendritic 5-HT1A and nerve terminal 5-HT1B autoreceptors,
SNRIs (and MAOIs) only the somato-dendritic ones [see e.g. (Blier and
El Mansari, 2013)]. Differences like these may underlie the different re-
sults obtained with SSRIs versus SNRIs.
Another important potential target of VLX effects could have been
the Galp gene. Galp encodes two proteins, galanin-like peptide and
alarin. Since Galp's expression is limited to speciﬁc neurons in the hypo-
thalamus (Jureus et al., 2000, 2001), our results may very well reﬂect
alarin expression in DaAg rats. In support of the previous notion,
Eberhard et al. demonstrated abundant alarin mRNA levels in the HC
and FC of mice (Eberhard et al., 2012), similar to our results in the cur-
rent experiment (see. Table 2.). The expression values, since microarray
experiments are normalized both within and between arrays, may
provide some rough insight in the relative expression of galanin
system's transcripts within these regions. Our data show Galp having
a higher signal than Gal1 or Gal3 within all three examined brain re-
gions, suggesting that alarin may play important roles in these areas
in rats. Please note, however, that the dissected brain regions are not
well-characterized and do not allow us to draw explicit conclusions.
Moreover, microarray experiments are not primarily designed to evalu-
ate absolute expressions of differential transcripts due to the vast number
of possible normalization and background correction methodologies.
Recently, Wang et al. demonstrated that i.c.v. administered alarin
shows potential anti-depressive effects, accompanied by an upregula-
tion of brain-derived neurotrophic factor in the prefrontal cortex and
HC of depression-like mouse model (Wang et al., 2014). In addition,
alarin also substantially inﬂuenced the levels of key hormones of the
HPA axis in the same experiment, andmore recent results suggest an in-
volvement of TrkB and pro- and anti-inﬂammatory cytokines in the
anti-depressive effects of alarin (Wang et al., 2015; Zhuang et al.,
2016). While SSRIs may or may not include the modulation of alarin
in their therapeutic efﬁcacy, the lack of effects of the antidepressant
VLX emphasizes, similarly to galanin and its receptors, alarin as poten-
tial target for future therapeutic agents.
4. Limitations and potential further studies
Finally, we have to raise attention to the limitations of the current
study. First, we have to note that mRNA levels do not necessarily reﬂect
appropriate protein levels; translationmay occur at different degrees, or
not at all. Second, dissected brain regionsmay be too large, and focusing
on the role of subregions using laser dissection and/or in situ hybridiza-
tion may reveal interesting results. For example sertraline-induced
expression differences in the galanin gene are known to exist along
the ventral–dorsal axis in the HC (Yamada et al., 2013). Third, multiple
hypothesis testingmay result in a signiﬁcant amount of false positive re-
sults. To avoid such bias we decreased signiﬁcance criterion to 0.001 for
theminPplr method and used the false discovery ratio to obtain adjust-
ed p-values when ﬁtting linear models. Fourth, the effect of VLX should
be studied in depression models, e.g. strong stress. Fifth, species/strain
differences in the expression of the galanin system are known to exist
(Le Maitre et al., 2013). For example, galanin is expressed in the 5-HT
neurons in the rat DR, but not in mouse and human. Thus, comparisons
between species with regard to antidepressant effects of various types
of monoamine reuptake inhibitors should be made with caution. In ad-
dition, the expression of Galp observed in our study within the DRmay
reﬂect strain differences, since Eberhard et al. could not demonstrate
similar expression levels in mice (Eberhard et al., 2012). Sixth, we
have not directly validated the individual genes presented in the current
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through other genes which resulted in overall more than 220 data
points comparing the microarray and qRT-PCR data, providing good
correlations (in the ﬁeld of microarrays) and highly signiﬁcant
p-values. Furthermore, our statistical calculations were compared to
the results of another acceptedmethod in the ﬁeld to reduce the chance
of statistical errors and further support our conclusions.
5. Conclusions
We show that chronic VLX treatment fails to alter the gene expres-
sion of galanin, Gal1, Gal2, Gal3 and Galp in the DR, FC and HC of normal
rats. These data suggest that the antidepressant therapeutic effect of
serotonin-noradrenaline reuptake inhibitors is not mediated by the ef-
fects on galanin, its receptors or alarin. Thus, the galanin receptors and
alarin remain promising therapeutic targets for about 40–50% of de-
pressed patients, who are therapy resistant for the currently used
antidepressants.
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